Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > FY2020 Drug Pricing Reform
FY2020 Drug Pricing Reform
-
Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
-
Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development
October 24, 2019
-
Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
-
Chuikyo Wary about Further Reduction in Generic Entry Prices
October 10, 2019
-
Chuikyo Positive to Add Sakigake Drugs for PMP Coverage, Nudges Industry to Show Counterproposal for Company Criteria
October 10, 2019
-
Chuikyo Supports Earlier Price Cuts for Certain Off-Patent Brand-Name Drugs
September 26, 2019
-
Show Us Concrete Proposals for Drug Pricing Reform: Kyokai Kenpo Director to Pharma
September 13, 2019
-
Chuikyo Agrees on Need to Look at More Examples to Craft Pricing Models for Cell & Gene Therapies
September 12, 2019
-
Both Payer, Doctor Members Want to Expand Comparator PMP Removal Rule, but Mixed on Timing: Chuikyo
September 12, 2019
-
Chuikyo Members Open to Post-Launch Premiums for Add’l Indications, but Call for Careful Application
September 12, 2019
-
9 Topics Presented towards 2020 Pricing Reform; Industry Hearing Slated for November-December: Chuikyo
September 12, 2019
-
Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
September 12, 2019
-
Chuikyo to Revisit Generic Price-Band Rule
July 26, 2019
-
Apply Essential Drug Price Maintenance Rule Soon after Unprofitability Re-Pricing: FPMAJ
July 25, 2019
-
Chuikyo Wraps Up 1st Round of Discussions on 2020 Medical Fee Revision
July 25, 2019
-
Chuikyo Cautious about Considering Societal Values in New Drug Pricing
July 25, 2019
-
Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
-
Regenerative Medicine Forum Opposes Lower Premium Rates for Cell & Gene Therapies, Wins Chuikyo Support for New Pricing Scheme
July 24, 2019
-
3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
July 24, 2019
-
Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…